The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment

被引：6
|
作者：
van den Heuvel, Lambertus P. [1 ,2 ,3 ]
van de Kar, Nicole C. A. J. [1 ]
Duineveld, Caroline [4 ]
Sarlea, Andrei [1 ]
van der Velden, Thea J. A. M. [1 ]
Liebrand, Wilhelmus T. B. [1 ]
van Kraaij, Sanne [2 ]
Schjalm, Camilla [5 ,6 ]
Bouwmeester, Romy [1 ]
Wetzels, Jack F. M. [4 ]
Mollnes, Tom E. [5 ,6 ,7 ,8 ,9 ]
Volokhina, Elena B. [1 ,2 ]
机构：
[1] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Pediat Nephrol, Amalia Childrens Hosp,Med Ctr, Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Lab Med, Nijmegen, Netherlands
[3] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium
[4] Radboud Univ Nijmegen, Med Ctr, Radboud Inst Hlth Sci, Dept Nephrol, Nijmegen, Netherlands
[5] Oslo Univ Hosp, Dept Immunol, Oslo, Norway
[6] Univ Oslo, Oslo, Norway
[7] Nordland Hosp, Res Lab, Bodo, Norway
[8] Univ Tromso, KG Jebsen TREC, Tromso, Norway
[9] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res, Trondheim, Norway
来源：
CELLULAR & MOLECULAR IMMUNOLOGY | 2020年 / 17卷 / 06期
关键词：
THERAPY;
D O I：
10.1038/s41423-020-0406-y
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：653 / 655
页数：3
相关论文
共 50 条
  • [1] The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment
    Lambertus P. van den Heuvel
    Nicole C. A. J. van de Kar
    Caroline Duineveld
    Andrei Sarlea
    Thea J. A. M. van der Velden
    Wilhelmus T. B. Liebrand
    Sanne van Kraaij
    Camilla Schjalm
    Romy Bouwmeester
    Jack F. M. Wetzels
    Tom E. Mollnes
    Elena B. Volokhina
    Cellular & Molecular Immunology, 2020, 17 : 653 - 655
  • [2] Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab
    Puissant-Lubrano, Benedicte
    Puissochet, Sylvain
    Congy-Jolivet, Nicolas
    Chauveau, Dominique
    Decramer, Stephane
    Garnier, Arnaud
    Huart, Antoine
    Kamar, Nassim
    Ribes, David
    Blancher, Antoine
    CLINICAL IMMUNOLOGY, 2017, 183 : 1 - 7
  • [3] Activation of complement component C5 - Comparison of C5 convertases of the lectin pathway and the classical pathway of complement
    Rawal, Nenoo
    Rajagopalan, Rema
    Salvi, Veena P.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (12) : 7853 - 7863
  • [4] Magnetic bead based assays for complement component C5
    DiScipio, Richard G.
    Schraufstatter, Ingrid U.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2017, 450 : 50 - 57
  • [5] ECULIZUMAB THERAPY MONITORING: RESIDUAL HEMOLYSIS IN ALTERNATIVE PATHWAY TEST IS NOT CAUSED BY C5 ACTIVITY
    Van Den Heuvel, Bert
    Van De Kar, Nicole
    Sarlea, Andrei
    Van Kraaij, Sanne
    Van Der Velden, Thea
    Liebrand, Wilhelmus
    Duineveld, Caroline
    Bouwmeester, Romy
    Wetzels, Jack
    Mollnes, Tom Eirik
    Volokhina, Elena
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3288 - 3289
  • [6] Eculizumab therapy monitoring: Residual hemolysis in alternative pathway test is not caused by C5 activity
    van den Heuve, Lambertus
    Sarlea, Andrei
    Duineveld, Caroline
    Mollnes, Tom Eirik
    Wijnsma, Kioa
    Wetzels, Jack
    van de Kar, Nicole
    Volokhina, Elena
    MOLECULAR IMMUNOLOGY, 2018, 102 : 226 - 226
  • [7] THE CONVERSION OF HUMAN-COMPLEMENT COMPONENT C5 INTO FRAGMENT C5B BY THE ALTERNATIVE-PATHWAY C5 CONVERTASE
    DISCIPIO, RG
    BIOCHEMICAL JOURNAL, 1981, 199 (03) : 497 - 504
  • [8] AN ALTERNATIVE PATHWAY HEMOLYTIC ASSAY OF COMPLEMENT COMPONENT-C3
    JESSEN, TE
    BARKHOLT, V
    WELINDER, KG
    HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1982, 363 (09): : 1011 - 1011
  • [9] FAMILIAL DEFICIENCY OF C5 IN HUMANS - INTACT BUT DEFICIENT ALTERNATIVE COMPLEMENT PATHWAY ACTIVITY
    MCLEAN, RH
    PETER, G
    GOLD, R
    GUERRA, L
    YUNIS, EJ
    KREUTZER, DL
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1981, 21 (01): : 62 - 76
  • [10] Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
    Harder, Markus J.
    Kuhn, Nadine
    Schrezenmeier, Hubert
    Hoechsmann, Britta
    von Zabern, Inge
    Weinstock, Christof
    Simmet, Thomas
    Ricklin, Daniel
    Lambris, John D.
    Skerra, Arne
    Anliker, Markus
    Schmidt, Christoph Q.
    BLOOD, 2017, 129 (08) : 970 - 980
12345